-
Endo To Enter A Year Of Recovery Following FDA Request To Pull Opana ER Off The Market
Friday, June 9, 2017 - 9:49am | 345Read More...Shares of Endo International plc - Ordinary Shares (NASDAQ: ENDP) were trading lower by more than 10 percent Friday morning in reaction to the U.S. Food and Drug Administration's request for the company to withdraw from the market its opioid painkiller called Opana ER. Stifel's Annabel Samimy felt...
-
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Monday, March 20, 2017 - 9:17am | 1119Read More...In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...
-
Citigroup Releases Endo Pharmaceuticals Core Product Trends; Explains Price Target
Tuesday, October 26, 2010 - 8:15am | 104Read More...Citigroup has released its Endo Pharmaceuticals Holdings (NASDAQ: ENDP) core product trends for the week ending 10/15/2010. Lidoderm, Opana, and Frova are among the medications featured in the report. “We arrive at our $40 price target for Endo based on a relative 2011 P/E multiple compared to the...
